SWX:KURN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Kuros Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KURN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: KURN's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

2.0%

KURN

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

-29.4%

KURN

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: KURN underperformed the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: KURN underperformed the Swiss Market which returned -0.4% over the past year.


Shareholder returns

KURNIndustryMarket
7 Day2.0%3.6%0.4%
30 Day-1.9%1.5%2.8%
90 Day2.5%2.0%5.8%
1 Year-23.4%-29.4%2.6%1.3%3.1%-0.4%
3 Year-78.9%-82.9%4.3%1.9%19.8%4.7%
5 Year-91.7%-93.5%71.8%66.0%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Kuros Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kuros Biosciences undervalued compared to its fair value and its price relative to the market?

0.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KURN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KURN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KURN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: KURN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KURN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KURN is good value based on its PB Ratio (0.7x) compared to the CH Biotechs industry average (3x).


Next Steps

Future Growth

How is Kuros Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kuros Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Kuros Biosciences performed over the past 5 years?

5.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KURN is currently unprofitable.

Growing Profit Margin: KURN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KURN is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare KURN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KURN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: KURN has a negative Return on Equity (-16.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is Kuros Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: KURN's short term assets (CHF17.7M) exceed its short term liabilities (CHF3.1M).

Long Term Liabilities: KURN's short term assets (CHF17.7M) exceed its long term liabilities (CHF5.6M).


Debt to Equity History and Analysis

Debt Level: KURN's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if KURN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KURN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KURN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 15.7% each year.


Next Steps

Dividend

What is Kuros Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KURN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KURN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KURN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KURN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KURN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Joost de Bruijn (54 yo)

3.08yrs

Tenure

CHF365,100

Compensation

Prof. Joost D. de Bruijn, B.Sc. Ph.D., has been Chief Executive Officer of Kuros Biosciences AG since December 4, 2017 and its Director since June 14, 2018. Prof. Dr. de Bruijn served as the Chief Executiv...


CEO Compensation Analysis

Compensation vs Market: Joost's total compensation ($USD410.31K) is about average for companies of similar size in the Swiss market ($USD494.49K).

Compensation vs Earnings: Joost's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joost de Bruijn
CEO & Director3.08yrsCHF365.10kno data
Michael Grau
Chief Financial Officer2.92yrsno datano data
Alistair Irvine
Chief Business Officerno datano datano data
Phillippe Saudan
Chief Development Officer4.42yrsno datano data
Frank-Jan van der Velden
Head of Business Affairs & Finance of Kuros Biosciences B.V.no datano data1.06%
CHF 724.6k
Pascal Longlade
Chief Medical Officer2.33yrsno datano data
Oliver Kronenberg
Senior Legal Counselno datano datano data
Charlie Campion
Head of Global Marketing3yrsno datano data
John Griffin
Head of Commercial Operations2.75yrsno datano data
Virginia Jamieson
Consultant2.67yrsno datano data

2.9yrs

Average Tenure

58yo

Average Age

Experienced Management: KURN's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joost de Bruijn
CEO & Director3.08yrsCHF365.10kno data
Clemens van Blitterswijk
Chairman2.58yrsCHF64.80kno data
Oliver Walker
Independent Non-Executive Director2.58yrsCHF46.80kno data
Scott Bruder
Independent Non-Executive Director2.58yrsCHF59.80kno data
Cato Laurentin
Member of Advisory Boardno datano datano data
Ralph Müller
Member of Advisory Boardno datano datano data
Norbert Boos
Member of Advisory Boardno datano datano data
Thomas Steffen
Member of Advisory Boardno datano datano data
Leanna Caron
Vice Chairman of the Boardno dataCHF50.20kno data
Richard Allen
Member of Strategic Advisory Board2.33yrsno datano data
Alpesh Patel
Member of Strategic Advisory Board2.33yrsno datano data
Kornelis Poelstra
Member of Strategic Advisory Board2.33yrsno datano data

2.6yrs

Average Tenure

54yo

Average Age

Experienced Board: KURN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.1%.


Top Shareholders

Company Information

Kuros Biosciences AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kuros Biosciences AG
  • Ticker: KURN
  • Exchange: SWX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF68.540m
  • Shares outstanding: 32.79m
  • Website: https://www.kuros.ch

Number of Employees


Location

  • Kuros Biosciences AG
  • Wagistrasse 25
  • Schlieren
  • Zurich
  • 8952
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSBT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2016
KURNSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJan 2016
YTSNDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2016
0RHRLSE (London Stock Exchange)YesCommon SharesGBCHFJan 2016

Biography

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the Uni...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:01
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.